[ad_1]
Acelyrin plans to increase its initial public offering to 26.5 million shares of its common stock.
The late-stage clinical biopharma company had previously said it would offer 20.6 million shares.
The IPO price will remain between $16 and $18 a share, Acelyrin said in a filing with the Securities and Exchange Commission on Wednesday.
Acelyrin…
[ad_2]
Source link
